Summary
This article discusses data from the ASSERT trial that was designed to test whether treatment with RVX-208, an oral drug that induces apolipoprotein A1 (apoA1) synthesis, would lead to increased apoA1 levels.
- Cardiology Clinical Trials
- Lipid Disorders
- Coronary Artery Disease
- © 2010 MD Conference Express
Tools
Benefits of Inducing ApoA1 Synthesis Still Unclear: Results from ASSERT
Permalink:
Table of contents
Cited By...
- No citing articles found.